The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
January 31st 2025
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.
5 Things to Know About Biosimilars and Inflammatory Bowel Disease
5 Things From the 36th Annual JP Morgan Healthcare Conference
The Switch From Filgrastim to a Cheaper Alternative: Tbo-Filgrastim
Amanda Forys on How Biosimilars Are Being Approached on the State Level